GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Medeze Group PCL (BKK:MEDEZE) » Definitions » Debt-to-EBITDA

Medeze Group PCL (BKK:MEDEZE) Debt-to-EBITDA : 0.03 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Medeze Group PCL Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medeze Group PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ฿4.3 Mil. Medeze Group PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ฿8.3 Mil. Medeze Group PCL's annualized EBITDA for the quarter that ended in Jun. 2024 was ฿472.3 Mil. Medeze Group PCL's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medeze Group PCL's Debt-to-EBITDA or its related term are showing as below:

BKK:MEDEZE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.06
Current: 0.06

During the past 0 years, the highest Debt-to-EBITDA Ratio of Medeze Group PCL was 0.06. The lowest was 0.00. And the median was 0.00.

BKK:MEDEZE's Debt-to-EBITDA is ranked better than
95.54% of 448 companies
in the Healthcare Providers & Services industry
Industry Median: 2.465 vs BKK:MEDEZE: 0.06

Medeze Group PCL Debt-to-EBITDA Historical Data

The historical data trend for Medeze Group PCL's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeze Group PCL Debt-to-EBITDA Chart

Medeze Group PCL Annual Data
Trend
Debt-to-EBITDA

Medeze Group PCL Quarterly Data
Mar23 Jun23 Mar24 Jun24
Debt-to-EBITDA - - 0.04 0.03

Competitive Comparison of Medeze Group PCL's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Medeze Group PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeze Group PCL's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Medeze Group PCL's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medeze Group PCL's Debt-to-EBITDA falls into.



Medeze Group PCL Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medeze Group PCL's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Medeze Group PCL's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.271 + 8.298) / 472.26
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Medeze Group PCL  (BKK:MEDEZE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medeze Group PCL Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medeze Group PCL's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medeze Group PCL Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Phutthamonthon Sai 4 Road, 28/9 Moo 8, Krathum Lom, Sam Phran, Nakhon Pathom, THA, 73220
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation, and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment.

Medeze Group PCL Headlines

No Headlines